Glyphic Biotechnologies is a Berkeley, California proteomics company founded in 2021 that is developing ProSE (Protein Sequencing by Expansion) — a de novo, high-throughput, single-molecule protein sequencing technology designed to discriminate all 20 amino acids and their post-translational modifications. - View it on GitHub